Telomir Pharmaceuticals
TELO
32 hedge funds and large institutions have $3.24M invested in Telomir Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 17 closing their positions.
2.21% less ownership
Funds ownership: 9.43% → 7.22% (-2.2%)
8% less capital invested
Capital invested by funds: $3.51M → $3.24M (-$269K)
26% less funds holding
Funds holding: 43 → 32 (-11)
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
+$111K |
| 2 |
PWM
Praetorian Wealth Management
Carmel,
California
|
+$30.2K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$30.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$22.3K |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$208K |
| 2 |
BlackRock
New York
|
-$119K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$94.7K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$80.5K |
| 5 |
Jane Street
New York
|
-$44.9K |
TELO Hedge Fund Activity: Q3 2025 in Review
32 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q3 2025, worth a combined $3.24M — down 7.7% from $3.51M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TELO and 6 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 6 added.
The largest buyer was Raymond James Financial, adding an estimated $111K. The largest seller was Goldman Sachs, cutting an estimated $208K.
- 32 institutional investors held Telomir Pharmaceuticals (TELO) as of Q3 2025, down from 43 in Q2 2025.
- Funds reported $3.24M of Telomir Pharmaceuticals stock for Q3 2025, down 7.7% quarter-over-quarter.
- 6 funds opened new Telomir Pharmaceuticals positions in Q3 2025 and 17 closed out, a net change of -11 holders.
- The largest Telomir Pharmaceuticals buyer in Q3 2025 was Raymond James Financial, an estimated $111K added.
- The largest Telomir Pharmaceuticals seller in Q3 2025 was Goldman Sachs, an estimated $208K sold.
Based on aggregated 13F filings for Q3 2025.